Vaxxas Pty Ltd

Business news, market intelligence, and global industry analysis.

The Latest

Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?

realme Buds T310 in Agile White: top true wireless earbuds under ₹2,000

realme Buds T310 review: Are these the best budget ANC earbuds under ₹2,000?

Why support-platform strategy may become a differentiator in schizophrenia treatment markets

Representative image of gold bars and tanker traffic in the Strait of Hormuz, illustrating why gold prices climbed to a one-month high even as the waterway was declared completely open.

What gold’s latest rally says about geopolitical hedging after the Strait of Hormuz reopening

Vaxxas Pty Ltd secures TGA aseptic manufacturing licence for HD‑MAP vaccine patches, unlocking clinical acceleration and strategic industry positioning

Vaxxas’ TGA licence unlocks GMP production for HD-MAP vaccines: What this means for clinical trials and global delivery strategy

Vaxxas Pty Ltd wins TGA manufacturing licence for needle‑free HD‑MAP vaccines, enhancing clinical scale and delivery potential. Find out what this means next.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

December 15, 2025